Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Medical Research and Opinion

• Publication date

  2006-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/030079906X100131PMID 16709304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.

  2006cited by this paper
• Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.

  2005cited by this paper
• Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.

  2005cited by this paper
• Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/Ameri

  2005cited by this paper
• Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.

  2004cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004influential reference
• Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo‐controlled, blinded experience in 2382 patients with primary hypercholesterolemia

  2004cited by this paper
• Drug prescriptions and referral to cardiac rehabilitation after acute coronary events: comparison between men and women in the French PREVENIR Survey.

  2004cited by this paper
• Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Efficacy and Safety of Coadministration of Ezetimibe and Statins in Elderly Patients with Primary Hypercholesterolaemia

  2004cited by this paper
• Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Statin Therapy in the Elderly

  2004cited by this paper
• Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.

  2004cited by this paper
• Consistency in Efficacy and Safety of Ezetimibe Coadministered with Statins for Treatment of Hypercholesterolemia in Women and Men

  2004cited by this paper
• Statin therapy in the elderly: does it make good clinical and economic sense?

  2003cited by this paper
• Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• The underlying risk of death after myocardial infarction in the absence of treatment.

  2002influential reference
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002influential reference
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

  2002cited by this paper
• Does increased aromatase activity in adipose fibroblasts cause low sexual desire in patients with HIV lipodystrophy?

  2002cited by this paper
• High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

  2001cited by this paper
• The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

  2000cited by this paper
• Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• Drug treatment of lipid disorders.

  1999cited by this paper
• Drug treatment of lipid disorders.

  1999cited by this paper
• Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

  1998influential reference
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

  1997cited by this paper
• Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.

  1990influential reference
• Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.

  1986cited by this paper

• LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial.

  2026cites this paper
• Italian Association of Hospital Cardiologists Position Paper ‘Gender discrepancy: time to implement gender-based clinical management’

  2024cites this paper
• Cardiovascular Medications

  2021cites this paper
• Management of Dyslipidemia in the Elderly

  2014cites this paper
• The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

  2013cites this paper
• Statins personalized.

  2012cites this paper
• Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes.

  2012cites this paper
• Описаны механизмы воздействия на всасывание холестерина. Рассмотрены ограничения при провеШ дении монотерапии статинами и преимущества использования комбинации статин и эзетимиб. Ключевые слова: Эзетимиб, всасывание холестерина, белок НиманаШ Пика, тип l1. Inhibition of cholesterol absorption in the

  2012cites this paper
• Using Primary Care Prescribing Databases to Determine Drug Switching and Continuation of Care

  2012cites this paper
• Inegy - Effective combination treatment to target LDL-C levels

  2012cites this paper
• Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia

  2011cites this paper
• Using Routinely Collected Prescribing Data to Determine Drug Persistence for the Purpose of Pharmacovigilance

  2011cites this paper
• Assessment and Treatment of Cardiovascular Disease in Obese Children

  2011cites this paper
• Lipid-lowering effects of ezetimibe and simvastatin in combination

  2011cites this paper
• The ezetimibe Jonah: the trials and tribulations of an unlucky drug

  2011cites this paper
• Ineffective statin monotherapy: alternative therapeutic strategy

  2011cites this paper
• Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.

  2011cites this paper
• Triglycerides and vascular risk: insights from epidemiological data and interventional studies.

  2009cites this paper
• Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category

  2009cites this paper
• Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.

  2009cites this paper
• Skuteczność połączenia ezetymibu/simwastatyny w dawkach 10/40 mg w porównaniu z podwójną dawką statyny u pacjentów hospitalizowanych z powodu ostrego incydentu wieńcowego: badanie INFORCE

  2009cites this paper
• Lipid-lowering drugs acting at the level of the gastrointestinal tract.

  2009cites this paper
• Lipid‐altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

  2008cites this paper
• Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care

  2008cites this paper
• C-reactive protein (CRP): more than just an innocent bystander?

  2008cites this paper
• Ezetimibe – An Overview of its Low-density Lipoprotein Cholesterol Lowering Efficacy

  2007cites this paper
• Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice

  2007cites this paper
• Emerging indications for statins: a pluripotent family of agents with several potential applications.

  2007cites this paper
• Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

  2007cites this paper
• Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia

  2006cites this paper
• Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview

  2006cites this paper